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Selection of aptamers against triple 
negative breast cancer cells using 
high throughput sequencing
Débora Ferreira1,2,4, Joaquim Barbosa1,2,4, Diana A. Sousa1,2, Cátia Silva1, Luís D. R. Melo1, 
Meltem Avci‑Adali3, Hans P. Wendel3 & Ligia R. Rodrigues1,2*
Triple‑negative breast cancer is the most aggressive subtype of invasive breast cancer with a poor 
prognosis and no approved targeted therapy. Hence, the identification of new and specific ligands 
is essential to develop novel targeted therapies. In this study, we aimed to identify new aptamers 
that bind to highly metastatic breast cancer MDA‑MB‑231 cells using the cell‑SELEX technology 
aided by high throughput sequencing. After 8 cycles of selection, the aptamer pool was sequenced 
and the 25 most frequent sequences were aligned for homology within their variable core region, 
plotted according to their free energy and the key nucleotides possibly involved in the target binding 
site were analyzed. Two aptamer candidates, Apt1 and Apt2, binding specifically to the target cells 
with K
d
 values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively, were further validated. The binding 
analysis clearly showed their specificity to MDA‑MB‑231 cells and suggested the targeting of cell 
surface receptors. Additionally, Apt2 revealed no toxicity in vitro and showed potential translational 
application due to its affinity to breast cancer tissue sections. Overall, the results suggest that Apt2 is 
a promising candidate to be used in triple‑negative breast cancer treatment and/or diagnosis.
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DAPI  4′,6-Diamidino-2-phenylindole
DMEM  Dulbecco’s Modified Eagle Medium
DMSO  Dimethyl sulfoxide
DOX  Doxorubicin
EGF  Epidermal growth factor
ER  Estrogen
FBS  Fetal bovine serum
HER2  Epidermal growth factor receptor 2
HTS  High throughput sequencing
Kd  Dissociation constant
MTT  3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide)
MUC1  Mucin 1
NGS  Next-generation sequencing
NSCLC  Non-small lung cancer cell cancer
PARP  Poly (ADP-ribose) polymerase
PBS  Phosphate-buffered saline
PR  Progesterone
RNA  Ribonucleic acid
SD  Standard deviation
SELEX  Systematic evolution of ligands by exponential enrichment
SL  Stem-loop
ssDNA  Single-stranded deoxyribonucleic acid
TNBC  Triple-negative breast cancer
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Breast cancer is the most commonly diagnosed cancer and the leading cause of death among women with nearly 
2.1 million new cases diagnosed and 630,000 deaths in  20181. Triple-negative breast cancer (TNBC) is a het-
erogeneous subtype of breast cancer, characterized by the absence of receptors for estrogen (ER), progesterone 
(PR), and epidermal growth factor receptor 2 (HER2) that represents approximately 15% of all breast cancer 
cases. TNBC patients have a worse prognosis comparing to other breast cancer subtypes due to its aggres-
sive and metastatic nature, elevated rates of relapse, and a low response to current  therapies2–4. Conventional 
chemotherapy has been the only systemic treatment option for early and advanced TNBC  disease5. However, 
recently published advances have shown exciting results with poly (ADP-ribose) polymerase (PARP) inhibitors 
and immunotherapy  agents6–8.
An emerging strategy in tumor-targeted therapies consists of using specific ligands, such as aptamers that are 
able to bind a variety of targets including proteins, small molecules, viruses, bacteria and live cells with high affin-
ity, specificity and  selectivity9–11. Aptamers exhibit many advantages over other ligands, such as the antibodies, 
since they can be easily synthesized and chemically modified, are non-toxic, and possess rapid tissue penetration 
and low  immunogenicity12. Aptamers are short single-stranded deoxyribonucleic acid (ssDNA) or ribonucleic 
acid (RNA) oligonucleotides derived from random oligonucleotide libraries through an in vitro iterative method 
so-called Systematic Evolution of Ligands by EXponential Enrichment (SELEX), which involves repetitive rounds 
of partitioning and enrichment commonly performed with purified target proteins immobilized on a solid 
 support13,14. Cell-SELEX enables the generation of aptamers directed towards cell-surface molecules by using 
whole living cells as  targets11,15. It allows the screening of cell-specific aptamers without any prior knowledge 
of molecular signatures of the target cells, besides offering the unique ability to target specific phenotypes by 
performing positive–negative selection cycles to find proteins only present on the target  cells16,17. This proce-
dure was successfully used for selecting breast cancer targeting  aptamers18,19. For instance, Liu et al.16 selected a 
ssDNA aptamer against MCF-7 breast cancer cells able to differentiate between breast cancer molecular subtypes.
However, the identification of new specific-target aptamers has been challenging mainly due to difficul-
ties related to the characterization of the potential sequences from enriched libraries. Usually, the identifica-
tion of enriched sequences is mainly performed by cloning and Sanger sequencing of the library resulting 
from several selection  cycles16,20. Therefore, only sequenced clones are identified as possible targeting ligands, 
excluding candidate aptamers with good performances but with low copy numbers in the enriched library. To 
overcome this issue, specialized technologies have been incorporated into the original SELEX process such as 
high throughput sequencing (HTS) and bioinformatics analysis. HTS and bioinformatics combined with SELEX 
(HT-SELEX) enable the identification of a large number of aptamer candidates, total reads, frequencies of each 
unique sequence, distribution of each nucleotide in the random sequence and the rate of molecular  enrichment21. 
Moreover, HT-SELEX allows identifying aptamers with high affinity and specificity at earlier selection rounds, 
which can greatly reduce over-selection which is time-consuming, and also avoid potential PCR artifacts in the 
amplification  steps22.
In this study, we combined cell-SELEX with next-generation HTS and bioinformatics analysis to select ssDNA 
aptamer sequences that specifically bind to the metastatic TNBC cell line MDA-MB-231. The selected aptam-
ers were further characterized and their affinity and specificity against the target cells were confirmed by flow 
cytometry and fluorescence microscopy. Moreover, the translational applicability of these aptamers was assessed 
using tumor tissue sections. Our results suggest that the selected aptamers are promising candidates for targeting 
and diagnosis applications in TNBC.
Results
Selection of aptamers against MDA‑MB‑231 cells through cell‑SELEX. In the first SELEX round, 
a positive selection was performed. The initial ssDNA library was incubated with MDA-MB-231 cells to obtain 
the maximum amount of ssDNA oligonucleotides binding to the target cells. From the 2nd round onwards, the 
negative control cells MCF-10-2A were introduced for counter-selection to eliminate any sequences recognizing 
surface molecules common to both cell lines, after which the unbound sequences were again incubated with the 
target cells for positive selection (Table S2). Finally, the ssDNA molecules bound to the target cells were amplified 
by PCR to be used in the next selection round. A total of 18th rounds of selection were conducted. PCR results 
from each selection round were monitored by electrophoresis, showing the band for enriched ssDNA pool equal 
to the initial library with about 90 nucleotides (nt) (data not shown). Flow cytometry was used to monitor the 
enrichment of the ssDNA pool with binding sequences after the 4th, 5th, 8th, 13th and 17th rounds. The binding 
ability and specificity of the enriched ssDNA pools were evaluated by incubation with target or control cells and 
detection of the fluorescence signal. As shown in Fig. 1A, the fluorescence signal with target MDA-MB-231 cells 
was gradually increased after incubation with the enriched ssDNA pools up to the 8th round. Also, a significant 
difference between the fluorescence intensity for negative control and target cells after incubation with FAM-
labelled ssDNA pools was observed. The results suggest that enriched sequences specific to the target cells were 
obtained at the 8th round, binding to approximately 20% of the cell population. A decrease of fluorescence signal 
for the target cells after incubation with the subsequent ssDNA pools was observed, which can be explained by 
the over-selection that occurs due to PCR artifacts in the amplification steps of cell-SELEX process.
The progression of the selection process was also monitored by measuring the amount of ssDNA retained 
on cells after washing, obtained after PCR and ssDNA generation (Fig. 1B). These results show an enrichment 
of ssDNA sequences binding to MDA-MB-231 cells up to the 8th round. Hence, the ssDNA pool from the  8th 
round was further sequenced through Illumina MiSeq NGS.
Identification of ssDNA aptamer candidates aided by bioinformatics tools. Sequencing results 
after an initial filtration, adapter and constant primer binding region removal and length filtration (49 nt) led 
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to 4,699,206 total sequences, from which about 4,347,204 were unique sequences and 352,002 exhibited more 
than one copy in the entire sequenced pool (Table 1). The 25 most frequent oligonucleotide sequences (exhibit-
ing only the randomized region), retrieved by either Matlab or Geneious refining, are detailed in Table 2. These 
sequences were further aligned for homology within their variable core region (Fig. 2A, B) and plotted according 
to their free energy (Fig. 2C). The analysis of the nucleotide sequences within those sequences were performed 
regarding sequence alignment, phylogenetic relationship, and secondary structure prediction.
The aligned N49 regions showed some conserved sequences such as ‘GTTG’ (Apt2, 6, 7, 8, 11, 13–16, 18, 
23 and 25); ‘X1GCTGCX2’ where  X1 can be either T or A and  X2 can be G or C (Apt8 and 22); ‘TGGTX’ where 
X can be either C, T or G (Apt2, 8, 9 and 23); ‘X1TTG CCG X2’ where  X1 can be G or A and  X2 can be G, C or A 
(Apt2, 6, 8, 11, 15, 17, 23, 25); ‘XCAAGTX’ where X can be both either G or A (Apt5 and 6); ‘XGAGT’ where X 
can be T, C or G (Apt1, 4, 7, 8, 10, 11, 16, 19 and 21); ‘AAGT’ (Apt1-3, 5, 6, 8, 11, 14 and 21); ‘X1GGAGX2’ where 
 X1 can be G, A or C and  X2 can be G, T or C (Apt7, 8, 10, 11 and 21); and ‘GCCG’ (Apt2, 3, 5, 6, 8, 10, 11 and 
14–25) (Fig. 2A). Furthermore, the selected aptamer sequences showed a distinct evolutionary tree (Fig. 2B), 
where three main families of related aptamers were identified, meaning that they do not have a similar sequence 
for conserved nucleotides. Apt1, Apt12, Apt22, Apt4, Apt13, Apt11, Apt20, Apt8, Apt10 and Apt24 belong to 
one family; Apt3, Apt7, Apt16, Apt17, Apt15, Apt25, Apt21, Apt6, Apt9, Apt 14 and Apt18 to another; and Apt2, 
Apt19 and Apt23 to the last one. According to their free energy, Apt7 and Apt2 have the lowest free energy and 
Apt4 and Apt21 the highest ones (Fig. 2C). The lower the free energy, the more stable the secondary structure.
Secondary structures of the 25 selected aptamer sequences were predicted using the Mfold web server (ver-
sion 3.0, http:// www. unafo ld. org/ mfold/ appli catio ns/ dna- foldi ng- form. php)23 to find their folding characteristics 
considering the primer and random regions (Fig. 3A and Table S3). For instance, Apt5, 6, and 21 show one stem 
loop (SL) structure, whereas Apt2, 3, 7, 8, 10, 12, 14–18, 22, and 24 show two. Moreover, Apt1, 4, 6, 13, 20, 23, 
and 25 possess three SL structures, while Apt11 and Apt19 have four. Additionally, the nucleotides involved in 
the formation of the SL structures were investigated. The conserved sequence ‘GTTG’ is found in the SL region 
of Apt2, 6, 7, 13, 15, 16, 18, 25, thus meaning that these aptamers are able to recognize the same target, despite 
exhibiting overall a low homology and conservation with each other. Moreover, the motif ‘TTG CCG ’ is found 
Figure 1.  Monitoring the enrichment of the selected DNA libraries regarding the target cell line MDA-MB-231 
and MCF-10-2A cells used for counter selection steps during the cell-SELEX process. (A) Fluorescence 
intensities of target and negative control cells incubated with FAM-labelled ssDNA pools from the initial library 
(SB-F) to the seventeenth selection cycle. (B) Represented is the ssDNA amount bound to the MDA-MB-231 
cells from the first to the eighth selection cycle.




Correct sequences (49 nt) 4,699,206
Sequences (1 copy) 4,347,204
Sequences (> 1 copy) 352,002
Sequences (> 10 copies) 111
Sequences (> 20 copies) 38
Sequences (> 25 copies) 25
Sequences (> 30 copies) 17
Sequences (> 40 copies) 11
Sequences (> 50 copies) 9
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in a SL structure of Apt15 and 25; ‘CAAGT’ in Apt5 and 6; ‘GAGT’ in Apt7, 8 and 21; ‘AAGT’ in Apt 5, 6, 11, 14, 
21; ‘GGAG’ in Apt7 and 8; and ‘GCCG’ in Apt14-16, 19, 22 and 25.
Among the 25 selected aptamer sequences, two candidate aptamers (Apt1 and Apt2) were chosen based on 
their pool repeatability, as well as on their different conserved sequences and secondary structures. Both aptamers 
were synthesized with FAM labels to be used in the following characterization experiments.
Affinity properties of the of Apt1 and Apt2 against MDA‑MB‑231 cells. In order to evaluate the 
binding affinity of the aptamer candidates Apt1 and Apt2, their Kd values were calculated using Eq. (1). Fig-
ure 3B shows the aptamers binding saturation curves with the target MDA-MB-231 cell lines, leading to Kd 
values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively. Saturation curves with the negative control MCF-10-2A 
cell line for both aptamers are also shown.
To evaluate the ability of both aptamers to bind to MDA-MB-231 (target) and MCF-10-2A (control) cells, 
fluorescence microscopy imaging and flow cytometry were performed (Fig. 3C, D). The microscopy and cytom-
etry results are in very good agreement. Apt1 and Apt2 bound to about 75.2 ± 0.4% and 76.2 ± 1.9% of the over-
all MDA-MB-231 cell population, respectively. Furthermore, it is also shown that for MCF-10-2A, almost no 
positive signal was detected (1.3 ± 2.2% to Apt1 and 0.2 ± 0.5% to Apt2), thus confirming the specificity of both 
aptamers. The microscopy results clearly show a bright fluorescence signal for the MDA-MB-231 cell population 
after incubation with the aptamers, being more pronounced for Apt2. As expected, no fluorescence signal was 
observed for the control cells, thus corroborating the cytometry results.
Apt1 and Apt2 specifically target cell surface receptors. To investigate whether the incubation tem-
perature could affect the binding ability of both aptamers, MDA-MB-231 cells were incubated with them at 
different temperatures and then analyzed by flow cytometry. MDA-MB-231 cells showed similar fluorescence 
intensity patterns after incubation with both aptamers at both temperatures (4 °C and 37 °C), hence demon-
strating that the incubation temperature has almost no effect (p > 0.05) on the binding capacity of the selected 
aptamers (Fig. 4A). In addition, MDA-MB-231 cells, pretreated with trypsin or proteinase K for 3 and 10 min, 
were incubated with the FAM-labelled aptamers, and were further analyzed by flow cytometry. Both aptamers 
lost the binding ability to their target cells after treatment with either proteinase K or trypsin at both exposure 
times (Fig. 4B).
A co-localization experiment was also performed using the naturally fluorescent filipin and both labelled 
aptamers (Fig.  5A). Apt1 and Apt2 showed a notorious binding to the MDA-MB-231 cell membrane, 
Table 2.  Selected oligonucleotide sequence candidates. Twenty-five most frequent oligonucleotide sequences 
obtained after next-generation sequencing (NGS) of the 8th Cell-Selex cycle. Only the sequence corresponding 
to the random region is shown. Primer binding sites were neglected in this representation.
Aptamer ID Sequences (5′–3′) Copies
Apt1 ‘GCA TCC ACC GTG AAT ATT GTA ACG CTA TAT GTG AGT GGC TAA GTG CAC C’ 89
Apt2 ‘ATG TTG TTG CCG GGA CGC CTC CTT CAC CAA AGT TGG TGT CCC CAC CTA C’ 86
Apt3 ‘TCG GGT GAT GGG TGG ACA AAA GTT AGT AGC CGC GAG CCA CTG GCC CAG T’ 79
Apt4 ‘AAT GAG TGT CAT CCG ACT AAG ATC TAT TTT AAG CTC GAC TCG TTT GGC A’ 64
Apt5 ‘CGC GGT GTT ATG AGG GGA CAA GTA CAA ATC AAT GTC GCC GCG TAG CCG C’ 59
Apt6 ‘ATG CAA GTG TTG CCG CGC AAA CAA TGC CTC CTG CTT ATT TGT GCC ACC A’ 59
Apt7 ‘AGG GAG GTA GCG TGC CCA CCA GGA GTT TTG CGC TAT ACG ATG TTG CTG G’ 58
Apt8 GAT GAC TGG TCA TAC GCG CGA TAA GTA TAT GCT GCC ACC GGA GTT GCC G’ 56
Apt9 ‘GAC GAT GTG GTC CGC TGG AAT TTT GCG AGC CCG CTA TAT GAA ATC GCC A’ 56
Apt10 ‘CGC CAA GGT CCG GAA GCG GAG TTA GTA GCC GCG AAA TCA CTG GCC CTC A’ 49
Apt11 ‘ATG CCA TAC GAA GTT GCC GCG TAT TCT TTG CTA ACG CCA CCG GAG TAT G’ 49
Apt12 ‘CTG ACG ATC CGG GCC AAG ATA ATC TCT GCG ATC AGT CGC CAG TCT TTC G’ 38
Apt13 ‘GAT TAG TAC GCG CAT GTT GTC GTT TTT CGG AAC CAC CAG TAG CGT TCG C’ 37
Apt14 ‘CGA AGT TTG TAG CCG CGG AAC TAC TGG CAC GTC ATT GCG TAT CAG GTT G’ 36
Apt15 ‘TGG CCA TCG GTC TTG TTG CCG AGA CCC AGC TCT CCA CCA TTC CGA TCG C’ 35
Apt16 ‘CGA GTC GTG GGA TCT CCA CAA TCC GCC GAA TTA GTT GCG CCA CAC CAC A’ 34
Apt17 ‘TAG AGC CAC TGA ACC TTA CCT GGC CCT GCA GAA GGT GAA TTG CCG CGT A’ 31
Apt18 ‘CGC AGG GTG TAG CCG CGA TCC ACT GGG TTC TTC CGT TGT ACG TTG ACG G’ 29
Apt19 ‘AAT TGG ACA GTA TTA GCC AGT CGC CAT GAA CTC TTG AGT ACC ATC GCC G’ 29
Apt20 ‘GAC ATT ACC CAT CTA GAC GGG GGT TAT TCT TAG TAG CCG CGA AAC CGT G’ 29
Apt21 ‘CGC CGG TAT AAT TCG AAA CAT GAG TAT TAG TAA GTC GAG GAG CGG CCG C’ 28
Apt22 ‘GCC GTC CGT TCC CGC AAG GGT ATC CAC GTT CTT AGT TTG TAG CTG CGA G’ 28
Apt23 ‘TCC GCA TGG TTC AGA TAT GTT GCC GCC ACG AAA TGG CCA CCA ATG ACC T’ 28
Apt24 ‘ACA GAC GTG TTT GTA GCC GCG AAA CTA CTG GCA ACT TAC CCA AAT CTC G’ 25
Apt25 ‘GAG CAG TCG CCA CCG TAT CTA TTA CGA GAC TAT AGA ACG TTG CCG CGA C’ 25
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corroborating the cytometry results. In addition, to delineate cell cytoskeleton, MDA-MB-231 cells were stained 
with CF 568 Phalloidin and an observable green fluorescence (at a less extent than the observed with filipin due 
to the great amount of washes during the protocol) was also observed at the membrane level (Fig. S1). In the end, 
to trace the potential cellular uptake of both aptamers, cells were incubated with lysoSensor (Fig. 5B). Again, a 
membrane staining was clearly observed for both aptamers (pointed out by the green arrows) but, interestingly, 
it was also found some aptamer uptake, represented by the yellow dots (highlighted by the yellow arrows).
Apt1 and Apt2 are MDA‑MB‑231 cell‑specific. Binding assays against three additional TNBC cells 
(Hs 578T, MDA-MB-157 and MDA-MB-468) were also performed (Fig. 6). The binding specificity was eval-
uated by flow cytometry and microscopy. The aptamer binding affinity was significantly lower for Hs 578T 
(ρ ≤ 0.0001), MDA-MB-157 (ρ ≤ 0.0001) and MDA-MB-468 (ρ ≤ 0.0001) when compared to MDA-MB-231 cells. 
About 3.3 ± 0.2% and 3.3 ± 0.1%, 7.7 ± 0.7% and 6.3 ± 0.2%, 5.1 ± 2.2% and 2.9 ± 0.8% of the overall Hs 578T, 
MDA-MB-157 and MDA-MB-468 cell population was bound to the Apt1 and Apt2, respectively (Fig.  6A). 
Under microscopy, no detectable fluorescence was observed for TNBC cell lines in study (Fig. 6B). Moreover, 
the aptamer binding specificity was assessed for other two breast cancer cell lines, including MCF-7  (ER+,  PR+, 
 HER2-) and MDA-MB-453  (ER-,  PR-,  HER2+) by flow cytometry and microscopy (Fig.  S2). As observed in 
Fig. S2A, the binding signal was significantly decreased for MCF-7 (ρ ≤ 0.0001) and MDA-MB-453 (ρ ≤ 0.0001) 
as compared to the target MDA-MB-231 cells, with 9.0 ± 0.02% and 7.9 ± 5.2%, 2.0 ± 0.9% and 0.9 ± 1.1% of 
the overall population bound to Apt1 and Apt2, respectively. No measurable fluorescence was detected under 
microscopy (Fig. S2B).
Figure 2.  Primary structure, phylogenetic tree, and Gibbs free energy. (A) Multiple sequence alignments 
of the random region from the twenty-five top-ranked oligonucleotide sequences obtained after NGS of the 
eighth selection cycle. Highlighted sequences denoted the regions of homology. (B) Phylogenetic analysis of 
aptamer candidates’ sequences was performed using the Tree Builder function in Geneious software (Geneious 
version 9.1.4; https:// www. genei ous. com/). The tree distances and sequence relatedness were determined using 
a neighbor-joining model with no outgroup. (C) Gibbs free energy of the twenty-five most frequent aptamer 
sequences was calculated considering the flanking regions, at 37 °C, 187 mM  Na+ and 0.5 mM  Mg2+, using 
mfold web server (version 3.0, http:// www. unafo ld. org/ mfold/ appli catio ns/ dna- foldi ng- form. php).
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Apt2 could be used as a targeting moiety in targeted therapies. The effects of the selected aptam-
ers on MDA-MB-231 cells viability were evaluated at two-time intervals (24 and 48 h). Cell viability was assessed 
using the standard colorimetric MTT assay. MDA-MB-231 untreated cells were used as the positive control and 
normalized to 100% cell viability. As illustrated in Fig. 7, after 24 h of incubation with 250 nM of both aptamers, 
no significant survival rate change was found, suggesting that both are non-toxic. The same trend was found for 
Apt2 for a 48 h incubation. However, for Apt1, a significant decrease in cell viability (ρ ≤ 0.05) was observed at 
this exposure time. The morphological changes resulting from incubation of cells with both aptamers at different 
time points up to 24 h (non-toxic exposure time for both aptamers) were also studied. As shown in Fig. 7B, no 
observable differences between the different conditions were found for both aptamers.
Apt2 has the potential for translational application to clinical oncology. Besides the selected 
aptamer’s ability to recognize MDA-MB-231 cells, we further evaluated their ability to target breast cancer tis-
sues (Fig. 8). For that purpose, fluorescence microscopy was used to image breast tissue sections after incubation 
with both FAM-labelled aptamers and the library. A visible green fluorescence signal of FAM-labelled Apt2 was 
detected in human breast tissues and no visible signal was found either for Apt1 or library.
Figure 3.  Secondary structure, equilibrium dissociation constant determination and binding ability of the 
selected aptamers. (A) Predicted secondary structures for two aptamer candidates, Apt1 and Apt2, selected 
for further in vitro experiments. The presented predicted secondary structures were the ones with lowest ΔG, 
i.e. the highest stability using the temperature 37 °C, 187 mM  Na+, and 0.5 mM  Mg2+, as calculated using the 
mfold web server (version 3.0, http:// www. unafo ld. org/ mfold/ appli catio ns/ dna- foldi ng- form. php). Constant 
sequence regions are highlighted in black, and blue represents the random regions. (B) Binding curve of 
aptamers Apt1 and Apt2 with MDA-MB-231 and MCF-10-2A cells. The cells were incubated with increasing 
concentrations of FAM-labelled aptamers and assessed by flow cytometry. Equilibrium dissociation constants 
(Kd) (nM) were calculated using GraphPad Prism 7, under the non-linear fit model, one-site non-competitive 
binding to fluorescent population ratio at used aptamer concentrations. (C) Binding ability of FAM-labelled 
aptamers, Apt1 and Apt2, with MDA-MB-231 and MCF-10-2A cells at 37 °C assessed by flow cytometry. All 
data are expressed as the mean ± SD of three independent experiments. Two-way ANOVA indicates statistically 
significant differences within the group assessed by Sidak’s post-test and denoted as follows: ****ρ ≤ 0.0001. (D) 
Microscopy results expressing the fluorescence imaging of MDA-MB-231 (a and b) and MCF-10-2A (c and d) 
cells incubated with FAM-labelled Apt1 and Apt2 at 37 °C, respectively. (1) blue filter, nuclei stained with DAPI, 
(2) green filter, Apt1 or Apt2, and (3) merge of all filters (1 and 2).
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Discussion
Breast cancer is the worldwide leading cause of deaths among women, being TNBC the most aggressive subtype 
with no approved targeted therapy. The identification of new molecules such as aptamers able to specifically 
target breast cancer may lead to the development of novel targeted therapies. Herein, cell-SELEX was used to 
select specific aptamers against the human breast cancer cell line MDA-MB-231, which is a good TNBC model 
due to its aggressive and metastatic nature.
ssDNA aptamers were identified by cell-SELEX against MDA-MB-231 cells and using the normal breast cell 
line MCF-10-2A for counter-selection to exclude all aptamers that bind in a non-specific way to cancer cells. 
The enrichment of the ssDNA pool with binding sequences was monitored, being the ssDNA pool from the  8th 
round further sequenced by NGS. Afterwards, the sequencing results were filtered and the 25 most frequent 
oligonucleotide sequences were analysed regarding the sequence alignment and phylogenetic relationship. This 
type of analysis can provide useful insights on the evolutionary process and on key nucleotides that may be 
involved in the target binding  site24. The selected aptamer sequences showed a distinct evolutionary tree, where 
three main families of related aptamers were identified, meaning that they do not have a similar sequence for 
conserved nucleotides.
Based on this analysis, it is premature to affirm that these conserved sequences are part of the target bind-
ing without confirming whether these regions of interest can contribute to form stems, loops or bulges. All 
aptamer sequences exhibit a predicted folded-secondary structure with a degree of SL structures. From those, 
Figure 4.  Binding characterization of Apt1 and Apt2 aptamers to MDA-MB-231 cells. (A) Effect of incubation 
temperature on the binding ability of Apt1 and Apt2 in MDA-MB-231 cells. The cells were incubated with 
FAM-labeled Apt1 and Apt2 at 4 °C or 37 °C and analyzed by flow cytometry. (B) Binding ability of aptamers 
Apt1 and Apt2 with MDA-MB-231 cells treated with trypsin or proteinase K. The cells were treated with trypsin 
or proteinase K at 37 °C for 3 or 10 min and then incubated with FAM-labelled Apt1 or Apt2, respectively. The 
binding ability of FAM-labelled Apt1 and Apt2 was analyzed by flow cytometry. All data are expressed as the 
mean ± SD of three independent experiments. One-way ANOVA indicates statistically significant differences 
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two candidate aptamer sequences, Apt1 and Apt2, were chosen based on the sequences’ repeatability on the entire 
pool, but also on their different conserved sequences and secondary structures.
A growing number of delivery strategies using cell-specific aptamers as targeting ligands have been 
 proposed25,26, given their ability to distinguish small differences in the cell surface protein signature of het-
erogeneous cancer cells. Therefore, to determine the binding affinity of Apt1 and Apt2 towards MDA-MB-231 
cells, their Kd values were assessed, giving values of 44.3 ± 13.3 nM and 17.7 ± 2.7 nM, respectively. Various cell-
SELEX protocols have been developed to isolate cell-specific aptamers. Li et al.16 selected the aptamer LXL-1 
( Kd = 44 ± 8 nM) against MDA-MB-231 cells. More recently, another approach to select aptamers against circu-
lating tumor MDA-MB-231 cells was attempted. A panel of 5 specific aptamers were identified, from which the 
M3 aptamer displayed the highest affinity with a Kd of 45.6 ± 1.2  nM19.
In both abovementioned reports, MDA-MB-231 cell-specific aptamers were identified after Sanger sequenc-
ing. NGS revolutionized the aptamer field by increasing the number of reads from few (Sanger sequencing) to 
millions (HTS methods), thus increasing the probability of finding the best ligands for a given target. The Kd 
values of the aptamers identified in our work are comparable, in the case of Apt1, or with a higher affinity to the 
target (about 2.5-fold higher), demonstrated for Apt2. A possible explanation is the use of NGS that, as men-
tioned, enables the retrieval of aptamers with better affinity to the target cells. Even though, this assessment is 
not straightforward as aptamers were selected using different experimental setups, including different libraries 
and protocol conditions, making it difficult to do a side by side comparison.
Aptamer selection at other temperatures rather than 37 °C, for instance, 4 °C, may result in poor binding 
ability at the physiological  temperature27. However, ssDNA could be non-specifically taken up at physiological 
Figure 5.  Co-localization of Apt1 and Apt2 with MDA-MB-231 cells. FAM-labelled Apt1 and Apt 2 were 
incubated at 37 °C with MDA-MB-231 cells and then with filipin (A) and lysoSensor Red DND-99 (B). (A) 
Fluorescence imaging of MDA-MB-231 cells stained with filipin (1) and incubated with FAM-labelled (2) Apt1 
(a) and Apt2 (b). White arrows point out membrane staining overlay with aptamer binding (3). (B) Confocal 
images of MDA-MB-231 cells labelled with lysoSensor (1) to track lysosomes location and incubated with 
FAM-labelled (2) Apt1 (a) and Apt2 (b) at 37 °C. Merged files are representative of co-localization of Apt1 and 
Apt2 with lysosensor (3.1). Images were obtained under confocal scanning laser microscope using a 60X oil 
immersion objective. Green arrows point out membrane location of FAM-labelled Apt and yellow ones the 
co-localization of FAM-labelled Apt with lysoSensor. Insert: co-localization of FAM-labelled Apt1 and Apt2 
with lysoSensor observed in 2 optical sections of MDA-MB-231 cells (3.2 and 3.3).
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temperatures by cells through a complex process called endocytosis that occurs via receptor-mediated pathways 
(clathrin-mediated, caveolae-mediated, macropinocytosis and clathrin and caveolae-independent pathways)28. 
Therefore, MDA-MB-231 cells were incubated with both aptamers at different temperatures, showing similar 
fluorescence intensity patterns.
To preliminary assess whether putative targets of these aptamers are membrane proteins on the cell surface, 
MDA-MB-231 cells were pre-treated with either trypsin or proteinase K, where both aptamers showed loss 
of binding ability. These results suggest that the target of both aptamers is associated with epitopes on the cell 
surface proteins, since proteinase K and trypsin are able to digest extracellular domains of the cell surface with-
out disrupting other components present in the cytosol. Moreover, incubation with filipin showed a clear co-
localization with Apt1 and Apt2 at the membrane. Filipin is a naturally fluorescent polyene antibiotic that binds 
to cholesterol, and because of that, has been widely used as a probe for sterol location in biological  membranes29.
In addition, to determine if both aptamers have the ability to be internalized upon target membrane bind-
ing, MDA-MB-231 cells were incubated with Apt1 or Apt2 and stained with lysoSensor, for fluorescent staining 
of acidic organelles as lysosomes. A strong accumulation of aptamer on the cell outer margins (pointed out by 
the green arrows) was again observed, corroborating the abovementioned results. Interestingly, a yellowish 
signal (highlighted by the yellow arrows) originated inside the cells and co-localized with lysoSensor was also 
observed. The results suggest that the target molecule of Apt1 and Apt2 is very likely a membrane protein and 
can be further internalized into cells.
Other authors also identified aptamers that are able to target membrane proteins and afterward are internal-
ized. TLS11a is an aptamer generated by cell-SELEX that exhibit a great affinity against the liver cancer  cells30,31. 
Meng et al.30 demonstrated the internalization ability of TLS11 upon targeting the cell membrane of LH86 cells. 
These authors generated a selective TLS11a aptamer-doxorubicin (DOX) complex to deliver DOX to liver cancer 
Figure 6.  Binding specificity of Apt1 and Apt2 aptamers to other TNBC cell lines. (A) FAM-labelled Apt1 and 
Apt2 were incubated at 37 °C with Hs 578T, MDA-MB-157 and MDA-MB-468 cell lines and analyzed by flow 
cytometry. Two-way ANOVA indicates statistically significant differences within the group assessed by Sidak’s 
post-test and denoted as follows: ****ρ ≤ 0.0001, ***ρ ≤ 0.001 and **ρ ≤ 0.001. (B) Microscopy results showing the 
fluorescence imaging of Hs 578T (a and b), MDA-MB-157 (c and d) and MDA-MB-468 (e and f) cells incubated 
with FAM-labelled Apt1 and Apt2 at 37 °C, respectively. (1) blue filter, nuclei stained with DAPI, (2) green filter, 
Apt1 or Apt2, and (3) merge of all filters (1 and 2).
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cells. Based on our results, the aptamer’s ability to target membrane receptors and subsequent internalization 
upon binding, makes them interesting for the development of targeted drug delivery systems and/or specific 
diagnosis methods. Moreover, it also proves the clear potential of cell-SELEX to generate specific ligands to target 
molecules in types of cancer that offer limited treatment options. Nevertheless, identifying the receptor(s) for 
these aptamers remains an open question worthy of further investigation.
As previously described, none of the selected aptamers were able to bind the non-tumorigenic epithelial 
human breast cell line MCF-10-2A, suggesting their specific binding to the target MDA-MB-231 cells. However, 
it was not clear if these aptamers could bind or recognize other TNBC cell lines, as Hs 578T, MDA-MB-157 and 
MDA-MB-468. No detectable fluorescence was observed, implying that the selected aptamers recognize cell 
surface receptors only present in MDA-MB-231 cells, but absent in the other cell lines assayed. Experiments 
with non-TNBC cell lines, as MCF-7 and MDA-MB-453, were also conducted to infer specificity and again no 
fluorescence was detected. MDA-MB-231, Hs 578T and MDA-MB-157 are highly invasive cell lines that have 
been grouped as basal B by Neve et al.32 or even characterized as mesenchymal-like by Lehmann et al. in a later 
 study33. Contrarily, MDA-MB-468 was grouped by both research teams as basal A. Finding such aptamers able 
to stratify such similar TNBC cell lines could be very promising, besides providing insights about novel thera-
peutic cell-surface targets.
Aptamers need different times to interact with their targets and to produce a cellular  response34. Furthermore, 
toxicity is a key limiting factor in the clinical translation and applicability of aptamers. Cell viability was assessed 
using a standard colimetric experiment that showed that for Apt2 no significant survival rate change was found, 
independently of the time assayed. However, for Apt1 a significant decrease in cell viability was observed at time 
point 48 h. The mechanisms underlying the cell viability decrease mediated by Apt1 are not fully understood. 
Based on these results, we foresee that Apt2 is stable enough for subsequent in vivo studies and possibly will also 
be useful for future clinical applications.
Aptamers can be used as therapeutic moieties covalently or non-covalently conjugated with a drug to form 
aptamer-drug conjugates to increase the therapeutic response on target  cells35. In addition, aptamers can be 
conjugated to nanoparticles such as liposomes, micelles, polymeric nanoparticles and quantum dots to carry 
anti-cancer drugs, and to guide the therapeutic reagents to the target  cells35. Hu et al.36 exploited the target-
ing ligand Mucin 1 (MUC1) aptamer for carrying DOX to cancer cells. DOX was intercalated into the DNA 
aptamer MA3, which binds to MUC1, to generate an aptamer-DOX complex. The complex was able to carry 
DOX into MUC1 positive tumor cells but lowered the toxicity to MUC1 negative cells. This indicates that the 
aptamer MA3 has the potential to be used for the targeted delivery of a therapeutic agent to MUC1 expressing 
 tumors36. Moreover, there are several aptamers able to internalize cells and inhibit proliferation or induce death. 
Wang et al.37 studied the effects on cell viability of a non-small lung cancer cell cancer (NSCLC)-specific RNA 
aptamer generated by in vivo SELEX. The chemically synthesized RNA aptamer and truncated form were able 
to inhibit the cell viability of NCI-H460 cells in a dose-dependent manner, exhibiting  IC50 values of 118.4 nM 
Figure 7.  In vitro toxicity of Apt1 and Apt2. (A) Cell viability was evaluated by MTT assay. MDA-MB-231 cells 
were incubated with Apt1 and Apt2, respectively, for 24 and 48 h. The ssDNA library was used as a negative 
control. All data are expressed as the mean ± SD of three independent experiments. Two-way ANOVA indicates 
statistically significant differences within the group assessed by Sidak’s post-test and denoted as follows: *ρ ≤ 0.1 
and ns ρ > 0.05. (B) Microscopy images of MDA-MB-231 cells treated with Apt1 or Apt2 for 0 h, 3 h, 6 h, 8 h, 
and 24 h. Non-treated cells were used as negative controls.
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and 105.7 nM,  respectively37. In this sense, our Apt1 could be further explored as a possible cell death inducer 
due to the significant decrease of cell viability observed.
Besides the proved aptamer’s ability to recognize MDA-MB-231 cells, the ability to target breast cancer tissues 
was also evaluated. A notorious green fluorescence signal was found for Apt2, reinforcing and supporting the 
potential translation of Apt2 to clinical applications, which could be of great significance in TNBC treatment 
and detection. The ability of aptamers to recognize human cancer tissues has also been demonstrated by other 
researchers. Wang and co-workers38 described an aptamer against the receptor glucagon identified by cell-SELEX 
able to bind to the cell membrane of hepatic tissues. Duan and  collaborators39 identified a DNA aptamer that 
could be used for imaging clinical metastatic prostate cancer tissues.
Conclusions
In summary, we have successfully demonstrated a combined analysis pipeline to screen aptamers using cell-
SELEX aided by a high throughput aptamer identification method to increase the success of aptamers selection 
against the target MDA-MB-231 cells. The selected aptamers obtained after 8 rounds of evolved enrichment were 
further aligned and the 25 most frequent oligonucleotide sequences were analyzed. Two aptamer candidates, 
Apt1 and Apt2, were characterized regarding their binding affinity to the target, with Kd values of 44.3 ± 13.3 and 
17.7 ± 2.7, respectively. Both aptamers seem to be associated with cell membrane epitopes only present in the 
target cells and these aptamers can be subsequently internalized. Apt1 and Apt2 toxicity were assessed showing 
little to no effect on cells, respectively. The potential translation to clinical applications was proven for Apt2 by 
immunofluorescence staining of tissue sections, thus highlighting its future potential as a ligand for targeted 
delivery in MDA-MB-231 TNBC tumors.
Material and methods
Cell lines and cell culture. Human breast cancer MDA-MB-231 (ATCC HTB-26) and non-tumorigenic 
epithelial human breast MCF-10-2A (ATCC CRL-10781) cell lines were used for the cell-SELEX as target cells 
and negative control, respectively. Hs 578T (ATCC HTB-126), MDA-MB-468 (ATCC HTB-132), MDA-MB-453 
Figure 8.  In vitro binding ability of Apt1 and Apt2 to human breast cancer tissue section detected through 
immunofluorescence staining. Control stands for experiments performed without FAM-labelled aptamer (a); 
with FAM-labelled ssDNA library (b) and with FAM-labelled Apt1 (c) and Apt2 (d), respectively. (1) blue filter, 
nuclei stained with DAPI and (2) green filter, FAM-labelled library, Apt1, or Apt2.
12
Vol:.(1234567890)
Scientific Reports |         (2021) 11:8614  | https://doi.org/10.1038/s41598-021-87998-y
www.nature.com/scientificreports/
(ATCC HTB-131), MCF-7 (ATCC HTB-22) and MDA-MB-157 (ATCC HTB-24) cell lines were also used to 
confirm the aptamers binding specificity. MDA-MB-231, Hs 578T, MDA-MB-468, MDA-MB-453, MCF-7 and 
MDA-MB-157 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) [Biochrom] supplemented 
with 10% Fetal Bovine Serum (FBS) [Biochrom] and 1% penicillin–streptomycin [Biochrom] on tissue culture 
treated flasks. MCF-10-2A cells were cultured in a 1:1 mixture of DMEM:Ham’s F12 medium [Biochrom] sup-
plemented with 20 ng/ml Epidermal Growth Factor (EGF) [Sigma], 100 ng/ml cholera toxin [Sigma], 0.01 mg/
ml insulin [Biochrom], 500  ng/ml hydrocortisone [Sigma], 5% horse serum [Biochrom] and 1% penicillin–
streptomycin. Cells were propagated at 37 °C, 5%  CO2 and 95% relative humidity. The cells were washed using 
phosphate-buffered saline (PBS) 1X pH 7.4 and were detached using Trypsin/EDTA solution [Biochrom]. Cells 
were counted in a hemocytometer using the trypan blue exclusion test.
Library, primers and buffers. A randomized ssDNA library with 49 nucleotides (nt) flanked by constant 
primer binding regions on both sides was used for the cell-SELEX (SB: GCC TGT TGT GAG CCT CCT AAC-nt49-
CAT GCT TAT TCT TGT CTC CC). The polymerase chain reaction (PCR) amplification was performed using a 
fluorescein labelled forward primer containing 21 nucleotides with an 18-carbon ethylene glycol spacer (P1-
F: 5′-FAM-[spacer-C18]-GCC TGT TGT GAG CCT CCT AAC-3′), and a 5′ end phosphate group reverse primer 
containing 20 nucleotides (P2-Ph: 5′-Phos-GGG AGA CAA GAA TAA GCA TG-3′). The fluorescein label enables 
the monitoring of the selection progress by flow cytometry and the antisense strand 5′ end with phosphate 
group helps the ssDNA preparation after each cell-SELEX cycle. Primers and library were HPLC-purified and 
purchased from Ella Biotech GmbH (Table S1). The binding buffer (BB) was prepared by supplementing PBS 
1X with 1 mM of  CaCl2·2H2O [Panreac] and 0.5 mM of  MgCl2·6H2O [VWR]. The washing (WB) and blocking 
buffers (BlB) were prepared from the BB by adding 0.02 mg/mL or 0.1 mg/mL bovine serum albumin (BSA) 
[Nzytech], respectively.
Cell‑SELEX procedure. About 2 ×  105 cells were plated on 6-well plates two days before the cell-SELEX. At 
the day of experiment, the culture medium was removed and cells were washed twice with BB and then incu-
bated for 1 min with BlB. The ssDNA library (2 nmol) was prepared in BB, denatured for 5 min at 95 °C, and 
cooled to down at room temperature for 10 min.
For the counter-selection, the initial library was incubated with MCF-10-2A cells for 30 min at 37 °C with 
gentle shaking. The library solution was collected and centrifuged at 0.3 g for 3 min and the supernatant was 
used for the selection step using the target MDA-MB-231 cells for 30 min at 37 °C with gentle shaking. After 
incubation, the supernatant was removed, and cells were washed with WB to remove unbound sequences. Cells 
were harvested from the well plate. Cells were heated for 10 min at 95 °C in DNAse-free water and cell-bound 
ssDNA oligonucleotides were amplified by PCR. Round by round the cell-SELEX stringency was augmented by 
increasing the number of washes after selection and reducing the number of cells for positive selection (Table S2).
ssDNA preparation. After each selection round, PCR reactions were performed on microtubes containing 
100 µL of PCR solution. Eluted ssDNA oligonucleotides obtained from each cycle were amplified using PCR 
MasterMix S [PeqLab] and primers (P1-F and P2-Ph) at a final concentration of 0.7 µM under the following 
conditions: 95 °C for 3 min, 15–25 cycles of 45 s at 95 °C, 45 s annealing at 78 °C and 1 min extension at 72 °C, 
followed by a final extension of 5 min at 72 °C. The PCR product was purified by MiniElute PCR purification kit 
[Qiagen]. The final dsDNA in the PCR purified product was separated by Lamba exonuclease digestion [New 
England  Biolabs]40. About 6.6 µg of purified dsDNA was incubated at 37 °C for 2 h with 25U of lambda exonu-
clease in 50 µL of total reaction volume. The reaction was stopped by incubation at 75 °C for 10 min. Purified 
PCR products were analyzed on a 10% denaturing urea-polyacrylamide gel and stained with GelRed [Biotium].
Sequencing and data analysis. The resulting ssDNA pool (from the 8th cycle) with the highest degree 
of enrichment was sequenced using Illumina MiSeq by Fasteris (Switzerland). The pool for sequencing was 
prepared by performing an overlap PCR with primers that are complementary to constant regions of the rand-
omized oligonucleotide library with an added overhang that includes an Illumina platform-specific sequence. 
Afterwards, the sequencing reads were filtered and demultiplexed. For this analysis, constant primer binding 
regions were removed and sequences longer or shorter than 49 nucleotides were discarded. Raw next-generation 
sequencing (NGS) data was analyzed using Matlab R2019a (The Mathworks, Inc.) and the alignment algorithm 
embedded in Geneious 9.1.4 software (Biomatters Ltd.; https:// www. genei ous. com/). The 25 most frequent oli-
gonucleotide sequences were further evaluated. The phylogenetic tree was constructed using Tree Builder func-
tion in Geneious, where the tree distances and sequence relatedness was determined by the method of Tamura 
and Nei using a neighbor-joining model with no outgroup. The free energy (∆G) and secondary structure were 
calculated using the Mfold software, presenting the optimal structure for each  aptamer23. The conditions used 
for the structure predictions were set according to the constituents of the BB at 37  °C in 187  mM  Na+ and 
0.5 mM  Mg2+ at pH 7.4.
Binding experiments. Flow cytometry. To monitor the cell-SELEX progress and the binding ability of 
the selected aptamers, flow cytometry analysis was performed. About 250 nM of FAM-labelled ssDNA pools 
or aptamers were incubated with 0.5 ×  105 target or negative (control) cells at 37 °C for 30 min. Cells were then 
washed, harvested, and finally resuspended in BB. The FAM-labelled ssDNA library (SB-F) was used as negative 
control.
To determine the equilibrium dissociation constant ( Kd ), MDA-MB-231 and MCF-10-2A cells were incubated 
with concentrations of FAM-labelled aptamers (Apt1-F and Apt2-F) ranging from 0 to 400 nM, in 200 µL of BB 
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at 37 °C for 30 min. SB-F was used as negative control. Cells were washed and harvested by using a cell scraper 
and then resuspended in 200 µL of BB for flow cytometry analysis. The Kd of the aptamer-cell interaction was 
determined by plotting the average total percentage of fluorescent cells (Y), against the concentration of aptamer 
(X, nM) and the  Bmax as the maximum number of binding sites, using a non-interacting binding sites model 
according to Eq. (1):
through GraphPad Prism (GraphPad Prism version 7.00 for Windows).
To evaluate the specificity of the selected aptamers, binding assays with other breast cancer cell lines (Hs 
578T, MDA-MB-157, MDA-MB-468, MDA-MB-453 and MCF-7) were performed. The fluorescence signal was 
measured using an EC800 flow cytometer analyzer [Sony Biotechnology] by counting at least 20,000 events.
Fluorescence microscopy. Fluorescence microscopy imaging was performed to monitor the binding affinity of 
the selected aptamers to live cells. About 2 ×  105 cells were seeded over coverslips in 6-well plates and cultured 
overnight. Subsequently, the cells were washed twice and incubated with 250 nM of Apt1-F and Apt2-F in BB at 
37 °C for 30 min. After washing with 500 µL WB, the cells were fixed with 4% paraformaldehyde (PFA) [Sigma] 
for 40 min at room temperature. After fixation, cells were once again washed of 4′,6-diamidino-2-phenylindole 
(DAPI) [Biotium] was added and incubated for 15 min at room temperature. The coverslips were placed in 
slides and the cells were observed in a fluorescence microscope [OLYMPUS BX51] incorporated with a high-
sensitivity camera Olympus DP71 at 10 × or 20 × magnification.
Effects of temperature and proteinase/trypsin treatment on aptamer binding ability. To per-
form a target-type analysis, MDA-MB-231 cells were treated with 0.1 mg/mL Proteinase K [Fisher BioReagents] 
or 0.25% trypsin [Sigma] solution for 3 or 10 min. In both cases, the incubation occurred at 37  °C and the 
reaction was stopped by adding 100 µL of DMEM with 10% (v/v) of FBS. Then, cells were washed twice and 
incubated with 250 nM of Apt1-F and Apt2-F at 37 °C for 30 min. After washing with WB, cell samples were 
analyzed by flow cytometry.
To ascertain the effect of temperature on the aptamer binding ability, MDA-MB-231 cells were incubated 
with 250 nM of FAM-labelled Apt1 and Apt2 at 4 °C or 37 °C for 30 min. After washing with WB, cell samples 
were analyzed by flow cytometry under the conditions previously described.
In vitro cytotoxicity assay. Cell viability was evaluated using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphe-
nyltetrazolium bromide) (MTT) assay [Sigma]. MDA-MB-231 and MCF-10-2A cells (1 ×  104 cells/well) were 
plated onto a 96-well plate in the day before the experiment. Cells were incubated for 24 and 48 h at 37 °C with 
250 nM of both aptamers, which were previously resuspended in BB, boiled at 95 °C for 5 min, and then cooled 
for 10 min at room temperature. SB was used as a negative control. After the incubation time, 100 µL MTT solu-
tion (0.5 mg/mL) was added to each well and cells were incubated at 37 °C for 4 h. Then, the MTT solution was 
removed and 150 µL of dimethyl sulfoxide (DMSO) [Sigma] was added to solubilize blue formazan crystals. The 
absorbance was read at 570 nm in a microplate reader [Cytation 3, BioTek].
Co‑localization studies. About 3 ×  104 cells were seeded on coverslips in 24-well plates and cultured over-
night. Cells were incubated with Apt1-F and Apt2-F in BB at 37 °C for 30 min and then were washed twice with 
WB.
For plasma membrane labelling, about 0.01 mg/ml of filipin [Sigma] dissolved in PBS 1X supplemented with 
0.5% BSA was added to cells right before imaging.
For actin filaments staining and cell cytoskeleton delineation, cells were fixed with 4% PFA for 40 min at 
room temperature. After rinsing with PBS 1X, cells were incubated with 50 mM ammonium chloride [Sigma] 
for 10 min, rinsed again and permeabilized with 0.1% of sodium dodecyl sulfate (SDS) Sigma) in PBS 1X for 
10 min. Next, cells were blocked in PBS 1X supplemented with 3% of BSA for 20 min and washed. Following this 
procedure, cells were incubated with CF 568 Phalloidin [Biotium] for 1 h in the dark in a humidified atmosphere. 
After incubation, cells were once again washed with PBS 1X with 0.1% of BSA, DAPI added and incubated for 
15 min at room temperature. Coverslips were mounted upside down in Vectashield mounting medium and the 
images were acquired in a fluorescence microscope [OLYMPUS BX51] incorporated with a high-sensitivity 
camera Olympus DP71, using a at 60X oil immersion objective.
To trace the cellular uptake of the aptamers, 1 mM of lysoSensor Red DND-99 [ThermoFisher] (1.5 µM final 
concentration) was added to each sample and incubated during 30 min at 37 °C. Next, the medium was removed 
and the coverslips were mounted upside down. Images were acquired in a sequential mode by a confocal scanning 
laser microscope (BX61 FLUOVIEW1000, Olympus), using a 60X oil immersion objective and with the specific 
filter settings for FAM (laser excitation line 488 nm and emissions filters BA 505–540, green channel) and RED 
DND-99 dye (laser excitation line 559 nm and emissions filters BA 575–675, red channel).
Fluorescence staining of breast cancer tissue sections. Tumor tissue fluorescence staining was used 
to confirm the aptamer’s ability to bind MDA-MB-231 tissues. Formalin-fixed paraffin-embedded breast can-
cer tissue sections were deparaffinized, rehydrated and then antigenic retrieval was performed as described 
 elsewhere41. Briefly, the slides were heated in 10 mM sodium citrate buffer pH 6.0 [Sigma] at 95 °C for 20 min 
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30 min at room temperature. Afterwards, the slides were incubated with 250 nM of Apt1-F, Apt2-F or SB-F in 
BB for 30 min at 37 °C and washed with WB. Finally, the slides were stained with Vectashield mounting media 
containing DAPI solution. Images were acquired using an Olympus BX51 microscope incorporated with a high-
sensitivity camera Olympus DP71 at 40X magnification.
Statistical analysis. Data were expressed as mean ± standard deviation (SD) of three independent experi-
ments. One-way ANOVA with Tukey’s post-test and two-way ANOVA with Sidak’s post-test were performed 
using GraphPad Prism to identify differences among multiple groups, considering a significance level of 95%.
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